Source disclosure: February 13, 2026
RaQualia Pharma Inc. [4579.T]
TOKYO, Feb 13 (Pulse News Wire) – RaQualia Pharma Inc. (4579.T) reported record revenue for the fiscal year ended December 2025, achieving operating profit of ¥483 million, ordinary profit of ¥437 million, and net profit of ¥273 million.
Revenue increased by 15% compared to the previous year, driven by strong performance in Korea and robust royalty income. The company also secured exclusive sales rights until 2031 after winning a patent dispute, ensuring sustained growth in the Korean market. Additionally, the U.S.
Phase III clinical trial for Teoprazan concluded successfully, with a regulatory filing completed on January 9, 2026. Looking ahead, RaQualia expects to maintain profitability through 2028, forecasting operating profits of ¥910 million by December 2028. The company plans to expand its global footprint, particularly in China and Europe, leveraging partnerships and ongoing development programs.
AI-translated content. 🔴 Confidence: Review recommended See terms • Original filing